奎扎替尼
|
|
IUPAC名 N-(5-tert-Butyl-1,2-oxazol-3-yl)-N′-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea
|
别名
|
|
识别
|
CAS号
|
950769-58-1 Y[PubChem]
|
PubChem
|
24889392
|
ChemSpider
|
24640357
|
SMILES
|
- CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
|
InChI
|
- 1/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
|
InChIKey
|
CVWXJKQAOSCOAB-UHFFFAOYAF
|
ChEBI
|
90217
|
DrugBank
|
DB12874
|
KEGG
|
D09955
|
IUPHAR配体
|
5658
|
性质
|
化学式
|
C29H32N6O4S
|
摩尔质量
|
560.67 g·mol−1
|
药理学
|
ATC代码
|
L01EX11(L01)
|
药品分级
|
|
若非注明,所有数据均出自标准状态(25 ℃,100 kPa)下。
|
奎扎替尼(Quizartinib)是一种用于治疗急性骨髓性白血病的药物,商品名为Vanflyta。[2]
它是一种小分子受体酪氨酸激酶抑制剂。其分子靶点是FLT3,也称CD135(一种原癌基因)。[3]
它在2019年10月在日本获许使用,[4]2023年7月在美国得到批准。[2]
参考文献
- ^ Vanflyta- quizartinib tablet, film coated. DailyMed. 26 July 2023 [6 August 2023]. (原始内容存档于7 August 2023).
- ^ 2.0 2.1 2.2 FDA approves quizartinib for newly diagnosed acute myeloid leukemia. U.S. Food and Drug Administration (FDA). 20 July 2023 [21 July 2023]. (原始内容存档于21 July 2023). 本文含有此來源中屬於公有领域的内容。
- ^ Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. December 2009, 52 (23): 7808–7816. PMID 19754199. doi:10.1021/jm9007533.
- ^ Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML (新闻稿). [16 February 2021]. (原始内容存档于2023-08-10).
外部链接
- Clinical trial number NCT02668653 for "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)" at ClinicalTrials.gov